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Serotonin (5-hydroxytryptamine, 5-HT) plays a crucial role in peripheral artery disease (PAD) and diabetes mellitus (DM). However, the precise molecular mechanisms how 5-HT causes progression of vascular dysfunction in these conditions are still an enigma. In the present study, we focused on the role of 5-HT in endothelial function both in vivo and in vitro using a selective 5-HT2A receptor blocker, sarpogrelate.
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In human EC, 5-HT markedly stimulated eNOS expression and the phosphorylation of eNOS, Akt and ERKI/2. In addition, a dose-dependent increase in tubule-formation on
Matrigel was observed after 5-HT treatment. In contrast, high glucose significantly inhibited tubule formation and eNOS expression through inactivation of Akt, while 5-HT significantly attenuated these actions of high glucose (P < 0.01). These results indicate that 5-HT stimulated angiogenesis through activation of Akt in ECs. However, in clinical situations, 5-HT seems to provide adverse effects. To examine the role of 5-HT in diabetic PAD, a hindlimb ischemia model was created in diabetic mice. The blood flow ratio of the ischemic to non-ischemic limb was significantly lower in DM mice than in normal mice, while sarpogrelate significantly attenuated the decrease in the blood flow ratio compared to control (P < O. OJ). Consistently, the decreased activity of eNOS and Akt in DM mice was significantly attenuated by sarpogrelate.
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Overall, the present study demonstrated that selective inhibition of 5-HT2A by sarpogrelate significantly restored ischemic limb blood perfusion in a severe diabetic mouse model through stimulation of the eNOS/Akt pathway via the endothelial 5-HTIB receptor. Enhancement of vasodi lation and angiogenesis by sarpogrelate might provide a unique treatment for PAD and DM patients.
